Short Communications 13
Schizophrenia and Pain - Preclinical

[SC13-3] A Rho-kinase 2 selective inhibitor KD025 ameliorates schizophrenia-like behaviors in MK-801-treated mice

*Rinako Tanaka¹, Yue Liu¹, Jingzhu Liao¹, Akihiro Mouri², Taku Nagai³, Toshitaka Nabeshima⁴, Kozo Kaibuchi⁵, Daiki Tachibana⁶, Yohei Kobayashi⁶, Norio Ozaki⁷, Hiroyuki Mizoguchi¹, Kiyofumi Yamada^1,8 (1. Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2. Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Toyoake, Japan, 3. Division of Behavioral Neuropharmacology, International Center for Brain Science (ICBS), Fujita Health University, Toyoake, Japan, 4. Laboratory of Health and Medical Science Innovation, Fujita Health University Graduate School of Health Sciences, Toyoake, Japan, 5. Division of Cell Biology, ICBS, Fujita Health University, Toyoake, Japan, 6. Pharmacology Research Unit, Sumitomo Pharma Co., Ltd., Osaka, Japan, 7. Pathophysiology of mental disorders, Nagoya University Graduate School of Medicine, Nagoya, Japan, 8. ICBS, Fujita Health University, Toyoake, Japan)

Keywords:Belumosudil, KD025, Rho-kinase, schizophrenia, MK-801